NEW YORK, NY / ACCESSWIRE / November 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (OTCQB: PBIO).

"We continue to see a steady flow of new interest in company's patented PCT platform for medical applications as well as drug discovery and cancer detection, which enhances the PBIO's growth prospects and industry standing. For example, on October 16, 2015, PBIO announced a partnership with Florida International University to develop and commercialize a PCT-based rape kit test method. The announcement follows research that PCT can enable a better method for extracting DNA from rape kits and other forensic samples," stated Ajay Tandon, CEO of SeeThruEquity. "PBIO has also made significant progress on shoring up its balance sheet. On September 28, PBIO disclosed that it had raised another $1.1mn in fresh capital from its existing $5mn private placement offering. The funds increased the gross capital raised by the private placement to $3.28mn - all of which took place after the close of 2Q15. The placement has allowed PBIO to clean up its balance sheet nicely as PBIO has used a portion of the proceeds to significantly reduce debt outstanding - convertible debt is down by nearly three quarters from a high of $2.6mn--and invest in growing its sales and marketing capabilities. We are maintaining our price target of $1.57 per share."

The report is available here: PBIO November 2015 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Additional highlights from the update note are as follows:

Improving fundamentals for PBIO evident in results, financing

As we highlighted in prior notes on PBIO, 2015 is shaping up to be a watershed year for the company. PBIO has made tremendous strides this year by improving its balance sheet and generating strong growth. The company generated "record" results in the first half of the year, with revenues of $0.85mn up 20% from year-ago levels. Importantly, the trend is expected to continue in the second half of the year, as PBIO begins to reap some of the rewards from new product development and its investment in marketing and sales. PBIO expects to eclipse $0.5mn in revenue in 3Q15, which would be a considerable milestone for the company as its annual run rate would surpass $2mn. Meanwhile, PBIO has made substantial progress cleaning up its balance sheet. Since the close of 2Q15, the company has raised $3.28mn in two tranches of a $5mn private placement, which we believe will close in coming weeks. PBIO has used the proceeds to reduce convertible debt - which was as high as $2.6mn - by nearly three quarters, and invest in sales and marketing operations. We believe the company also intends to pursue an up-listing to a national exchange in the future, pending meeting the requirements for such a move.

Steady flow of new potential applications of PCT

We continue to see a steady flow of interest in new potential medical applications of PCT, which enhances PBIO's growth prospects and industry standing, in our view. On October 16, 2015, PBIO announced a partnership with Florida International University (FIU) to develop and commercialize a PCT-based rape kit test method. The company also recently announced a two year collaborative partnership with the Institute of Bioinformatics, one of India's most prestigious not-for-profit scientific research organizations, which incorporates PBI's PCT platform in their search for biomarkers in a number of human diseases, including cancer and stroke.

Price target of $1.57 for PBIO

We have a price target of $1.57 for PBIO and see the company as an attractive, speculative growth company in the microcap health care sector. If achieved, the target represents potential upside of 554.2% from the recent price of $0.24.

Please review important disclosures on our website at www.seethruequity.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity